(lp0
S"ZIOPHARM Oncology, Inc.'s  stock price is Worth at $5.81 while ends ... Hot Stocks Point - Feb 21, 2017 USA based company, ZIOPHARM Oncology, Inc. 's latest closing price distance was at -0.96% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -6.85% and -8.93% compared with the 20 Day Moving&nbsp;..."
p1
aS"Can We Learn Anything From The Technical Chart of ZIOPHARM Oncology, Inc. ? NY Stock News - 14 hours ago ZIOPHARM Oncology, Inc.  has presented a rich pool of technical data in recent sessions. These are the trends we've been tracking and how we feel they should be played in the current environment."
p2
aS"Checking the Overall Picture for ZIOPHARM Oncology, Inc.  StockNewsJournal - 13 hours ago ZIOPHARM Oncology, Inc.  is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $6.69, up from yesterday's close by 13.78%.ZIOPHARM Oncology Inc  Soars 13.78% on March 27 - Equities.comZIOPHARM Oncology Inc.  Shares Rose 10% Following Positive Meeting with ... - Smarter Analyst"
p3
aS'ZIOPHARM Oncology Inc  Reviewed By Analysts The De Soto Edge - Jan 22, 2017 Stock market analysts watching ZIOPHARM Oncology Inc  have recently changed their ratings on the stock. The latest reports which are outstanding on Sunday 26th of March state 1 analyst has a rating of strong buy, 0 analysts buy, 4 analysts&nbsp;...'
p4
aS'Griffin Lifts Price Target on ZIOPHARM Oncology Inc.  Ahead of ... Smarter Analyst - Feb 9, 2017 Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. , particularly taking into account the seven clinical trials the firm has forthcoming on the table for this year; trials which the analyst commends as&nbsp;...'
p5
aS"Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics Motley Fool - Nov 3, 2016 And although it hasn't been as closely associated with CAR-T as Juno Therapeutics, Ziopharm Oncology  is part of a collection of entities  developing a therapeutic pipeline in the same class,&nbsp;...ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting - GlobeNewswire "
p6
aS'ZIOPHARM Oncology, Inc.  Technicals Are Painting A Bleak Picture USA Commerce Daily - 13 hours ago With all other things going on, ZIOPHARM Oncology, Inc.  has been on a run - rising 15.74 percent in just three months.'
p7
aS"The Reason Behind ZIOPHARM Oncology Inc.'s 11% Gain Motley Fool - Nov 10, 2016 Shares of ZIOPHARM Oncology , a clinical-stage biopharmaceutical company focused on the development of various immunotherapeutic cancer treatments, surged as much as 11% during Thursday's trading session after the company&nbsp;...Stock Update : ZIOPHARM Oncology Inc. Reports Third Quarter 2016 ... - Smarter Analyst"
p8
aS"Company Update : ZIOPHARM Oncology Inc. Announces 4Q:16 Financial ... Smarter Analyst - Feb 16, 2017 ZIOPHARM Oncology Inc.  announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company's recent activities.Ziopharm 4Q Loss 11 Cents a Share  - InvestopediaZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on ... - GlobeNewswire "
p9
aS'Griffin Commends ZIOPHARM Oncology Inc.  Following Suspension Of Breast ... Smarter Analyst - Feb 27, 2017 ZIOPHARM Oncology Inc.  has indicating the firm will be shifting its R&amp;D pipeline, centering its IL-12 gene therapy program on glioblastoma following the suspension of future development of its breast cancer therapy program.Sizling Stock Update: ZIOPHARM Oncology, Inc.  - HugoPressZIOPHARM Oncology Inc  Rating Lowered to Sell at Zacks Investment Research - Sports Perspectives'
p10
a.